Core Viewpoint - The ongoing dispute between Changchun Shengboma and New Oxygen Youth Clinic highlights the complexities of compliance and pricing mechanisms in the domestic medical beauty filler market, specifically regarding the product "Aivilan" [1][2] Group 1: Industry Dynamics - The traditional medical beauty market has seen supply-side dominance over pricing, where the cost of consumables, manufacturer profits, and channel premiums dictate the final price [2][5] - The pricing formula can be simplified as: Price = Consumable Cost + Manufacturer Profit + Channel Premium [2] - Manufacturers retain over 90% gross profit margins, leaving minimal profit for other channels and institutions [5][10] Group 2: Pricing Mechanisms - The pricing structure involves multiple layers of markup from manufacturers to distributors and ultimately to medical institutions, leading to significant price inflation [5][6] - For example, the market price of Juvederm Ultra 4 in South Korea is around 2000 RMB, while in first-tier Chinese cities, it can exceed 6000 RMB due to various markups [5][10] - Manufacturers employ various strategies to maintain price control, including supply adjustments, legal pressure on price-cutting distributors, and limiting access to authenticity verification channels [6][10] Group 3: Consumer Perspectives - Consumers often oppose the manufacturers' pricing logic, advocating for transparency and market-driven pricing rather than excessive premiums [2][15] - The dichotomy between the medical attributes of beauty services and their consumer aspects reflects a fundamental conflict in the industry [2][14] - The current pricing logic tends to overlook the value of medical services, leading to a focus on cost-cutting rather than enhancing consumer experience [10][12] Group 4: Future Considerations - A potential solution to the pricing dilemma is itemized pricing, which would reflect the comprehensive service experience rather than just the cost of consumables [11][13] - The industry should aim for a pricing model that allows for fair profit margins for manufacturers while ensuring quality service and safety for consumers [13][14] - Ultimately, the question of who determines medical beauty service prices should involve multiple stakeholders, reflecting a consensus rather than unilateral control [14][16]